HRP20161288T1 - Topikalni farmaceutski pripravci koji sadrže mometazon furoat - Google Patents
Topikalni farmaceutski pripravci koji sadrže mometazon furoat Download PDFInfo
- Publication number
- HRP20161288T1 HRP20161288T1 HRP20161288TT HRP20161288T HRP20161288T1 HR P20161288 T1 HRP20161288 T1 HR P20161288T1 HR P20161288T T HRP20161288T T HR P20161288TT HR P20161288 T HRP20161288 T HR P20161288T HR P20161288 T1 HRP20161288 T1 HR P20161288T1
- Authority
- HR
- Croatia
- Prior art keywords
- weight
- percent
- preparation
- preparation according
- weight percent
- Prior art date
Links
- 229960002744 mometasone furoate Drugs 0.000 title claims 7
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 title claims 7
- 239000012049 topical pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims 24
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims 12
- 229940051250 hexylene glycol Drugs 0.000 claims 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- 208000017520 skin disease Diseases 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 2
- 229930195733 hydrocarbon Natural products 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 2
- 239000003208 petroleum Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 claims 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003974 emollient agent Substances 0.000 claims 1
- 239000002085 irritant Substances 0.000 claims 1
- 229940057995 liquid paraffin Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940043348 myristyl alcohol Drugs 0.000 claims 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 1
- 229940055577 oleyl alcohol Drugs 0.000 claims 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 229940012831 stearyl alcohol Drugs 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (13)
1. Topikalni farmaceutski pripravak, naznačen time, da sadržava, u odnosu na ukupnu masu pripravka:
a) 0,01 do 0,2 težinskih postotaka mometazon furoata,
b) 5 do 18 težinskih postotaka heksilen glikola,
c) 20 do 40 težinskih postotaka vode i
d) 25 do 70 težinskih postotaka uljne faze, pri čemu je mometazon furoat suspendiran (raspršen) u pripravku.
2. Pripravak u skladu s patentnim zahtjevom 1, naznačen time, da je ukupna količina a) mometazon furoata u rasponu od 0,05 do 0,15 težinskih postotaka, poželjno od 0,08 do 0,12 težinskih postotaka s obzirom na ukupnu težinu pripravka.
3. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačen time, da je ukupna količina b) heksilen glikola u rasponu od 7 do 15 težinskih postotaka, poželjno 8 do 13 težinskih postotaka s obzirom na ukupnu težinu pripravka.
4. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da je ukupna količina c) vode u rasponu od 25 do 40 težinskih postotaka, poželjno 25 do 35 težinskih postotaka, još poželjnije 26 do 34 težinskih postotaka s obzirom na ukupnu težinu pripravka.
5. Pripravak u skladu s bilo kojim od patentnih prethodnih zahtjeva, naznačen time, da je ukupna količina d) uljne faze u rasponu od 30 do 65 težinskih postotaka s obzirom na ukupnu težinu pripravka.
6. Pripravak u skladu s patentnim zahtjevom 1, naznačen time, da se sastoji s obzirom na ukupnu težinu pripravka, od:
a) 0,01 do 0,2 težinskih postotaka, poželjno 0,05 do 0,15 težinskih postotaka mometazon furoata,
b) 5 do 18 težinskih postotaka, poželjno 7 do 15 težinskih postotaka heksilen glikola,
c) 20 do 40 težinskih postotaka, poželjno 25 do 35 težinskih postotaka vode i
d) 25 do 70 težinskih postotaka, poželjno 30 do 65 težinskih postotaka uljne faze.
7. Pripravak u skladu s patentnim zahtjevom 6, naznačen time, da sadržava, u odnosu na ukupnu masu pripravka:
a) 0,05 do 0,15 težinskih postotaka, poželjno 0,08 do 0,12 težinskih postotaka mometazon furoata,
b) od 7 do 15 težinskih postotaka, poželjno 8 do 13 težinskih postotaka heksilen glikola,
c) 25 do 35 težinskih postotaka, poželjno 26 do 34 težinskih postotaka vode,
d1) 32 do 50 težinskih postotaka, poželjno 35 do 48 težinskih postotaka naftnih ugljikovodika,
d2) 5 do 12 težinskih postotaka, poželjno 7 do 10 težinskih postotaka C6-C24 masnih alkohola i
d3) 0,1 do 5 težinskih postotaka, poželjno 0,5 do 3 težinskih postotaka bilo kojeg poliola osim heksilen glikola.
8. Pripravak u skladu s patentnim zahtjevom 7, naznačen time, da sadržava, u odnosu na ukupnu masu pripravka:
a) 0,08 do 0,12 težinskih postotaka mometazon furoata,
b) 8 do 13 težinskih postotaka heksilen glikola,
c) 26 do 34 težinskih postotaka vode,
d1) 35 do 48 težinskih postotaka naftnih ugljikovodika odabranih iz skupine koju čine tekući parafin, bijeli parafin ili njihove smjese,
d2) 7 do 10 težinskih postotaka C6-C24 masnih alkohola odabranih iz skupine koju čine lauril alkohol, miristil alkohol, palmitil alkohol, stearil alkohol, oleil alkohol ili njihove smjese i
d3) 0,5 do 3 težinskih postotaka glicerola.
9. Pripravak u skladu s bilo kojim od patentnih prethodnih zahtjeva, naznačen time, da pripravak nadalje sadržava sredstva protiv iritiranja, antioksidanse, pufere, sredstva za tvorbu helata, sredstva za ublaživanje, sredstva za pojačavanje penetracije, konzervanse, sredstva za pospješivanje otapanja, sredstva za zgušnjavanje, sredstva za vlaženje ili mješavine istih.
10. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da spomenuti pripravak ima pH vrijednost u rasponu od 3,0 do 6,0.
11. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da je pripravak formuliran u obliku kreme.
12. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time, da se rabi u liječenju ili prevenciji psorijaze, atopičnog dermatitisa i drugih kožnih poremećaja ili bolesti.
13. Uporaba pripravka u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačena time, da je namijenjena proizvodnji lijeka za liječenje ili prevenciju psorijaze, atopičnog dermatitisa i drugih kožnih poremećaja ili bolesti.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382146A EP2394653A1 (en) | 2010-05-26 | 2010-05-26 | Topical pharmaceutical compositions comprising mometasone furoate |
| US36505010A | 2010-07-16 | 2010-07-16 | |
| EP11719487.8A EP2575822B1 (en) | 2010-05-26 | 2011-05-13 | Topical pharmaceutical compositions comprising mometasone furoate |
| PCT/EP2011/002369 WO2011147536A2 (en) | 2010-05-26 | 2011-05-13 | Topical pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161288T1 true HRP20161288T1 (hr) | 2016-11-18 |
Family
ID=42797321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161288TT HRP20161288T1 (hr) | 2010-05-26 | 2016-10-06 | Topikalni farmaceutski pripravci koji sadrže mometazon furoat |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20140200203A1 (hr) |
| EP (2) | EP2394653A1 (hr) |
| JP (1) | JP5743241B2 (hr) |
| KR (1) | KR101790371B1 (hr) |
| CN (1) | CN102883725B (hr) |
| AR (1) | AR081765A1 (hr) |
| AU (1) | AU2011257586B2 (hr) |
| BR (1) | BR112012030006A2 (hr) |
| CA (1) | CA2794553C (hr) |
| CL (1) | CL2012003282A1 (hr) |
| CO (1) | CO6640244A2 (hr) |
| DK (1) | DK2575822T3 (hr) |
| EA (1) | EA022967B1 (hr) |
| ES (1) | ES2595250T3 (hr) |
| HK (1) | HK1177893A1 (hr) |
| HR (1) | HRP20161288T1 (hr) |
| HU (1) | HUE029818T2 (hr) |
| IL (1) | IL222163B (hr) |
| LT (1) | LT2575822T (hr) |
| ME (1) | ME02555B (hr) |
| MX (1) | MX2012013642A (hr) |
| MY (1) | MY160377A (hr) |
| NZ (1) | NZ602730A (hr) |
| PL (1) | PL2575822T3 (hr) |
| PT (1) | PT2575822T (hr) |
| RS (1) | RS55233B1 (hr) |
| SG (2) | SG184405A1 (hr) |
| SI (1) | SI2575822T1 (hr) |
| SM (1) | SMT201600342B (hr) |
| TW (1) | TWI473615B (hr) |
| UY (1) | UY33404A (hr) |
| WO (1) | WO2011147536A2 (hr) |
| ZA (1) | ZA201208420B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2394653A1 (en) | 2010-05-26 | 2011-12-14 | Almirall, S.A. | Topical pharmaceutical compositions comprising mometasone furoate |
| CN105392473B (zh) * | 2013-07-11 | 2018-06-08 | 宝丽制药股份有限公司 | 使用时产生泡沫状态的外用组合物 |
| GB2540764A (en) * | 2015-07-24 | 2017-02-01 | Fontus Health Ltd | Topical composition |
| CA3061238A1 (en) * | 2017-03-10 | 2018-09-13 | Rutgers, The State University Of New Jersey | Indole derivatives as efflux pump inhibitors |
| EP3492068A1 (en) * | 2017-12-01 | 2019-06-05 | NCP NewCare Products GmbH | Composition for treating onychomycosis |
| US20210322585A1 (en) * | 2020-04-21 | 2021-10-21 | Deloren E. Anderson | Silver titanium dioxide coating material, atomized silver titanium dioxide solution for inhaling and photocatalytic titanium dioxide solution for tattoo removal |
| CN114767630A (zh) * | 2022-06-06 | 2022-07-22 | 黑龙江中医药大学 | 一种治疗变应性鼻炎的药物组合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4808610A (en) | 1986-10-02 | 1989-02-28 | Schering Corporation | Mometasone furoate anti-inflammatory cream composition using hexylene glycol |
| US4775529A (en) | 1987-05-21 | 1988-10-04 | Schering Corporation | Steroid lotion |
| WO1991008733A1 (en) | 1989-12-20 | 1991-06-27 | Schering Corporation | Stable cream and lotion bases for lipophilic drug compositions |
| EP0735885B1 (en) | 1993-12-21 | 2004-07-28 | Schering Corporation | Ointments comprising mometasone furoate and salicylic acid for the topical treatment of psoriasis |
| US5696105A (en) * | 1996-03-14 | 1997-12-09 | Hackler; Walter A. | Antifungal nail composition |
| DE69804998T2 (de) | 1997-10-09 | 2002-12-12 | Schering Corp., Kenilworth | Mometasonfuroat-suspensionen zum zerstäuben |
| TR200201343A2 (tr) | 2002-05-17 | 2003-12-22 | Orva İlaç Sanayi̇ Ve Ti̇caret A. Ş. | Kortikosteroid ve antiseptik içeren farmasötik bileşim |
| US7312207B2 (en) | 2003-05-23 | 2007-12-25 | Taro Pharmaceuticals North America, Inc. | Topical steroid cream formulations |
| DE102006034883A1 (de) | 2006-07-25 | 2008-01-31 | Hermal Kurt Herrmann Gmbh & Co. Ohg | Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat |
| WO2008126076A2 (en) | 2007-04-11 | 2008-10-23 | Perrigo Israel Pharmaceuticals Ltd. | Low-dose mometasone formulations |
| EP2394653A1 (en) | 2010-05-26 | 2011-12-14 | Almirall, S.A. | Topical pharmaceutical compositions comprising mometasone furoate |
-
2010
- 2010-05-26 EP EP10382146A patent/EP2394653A1/en not_active Withdrawn
-
2011
- 2011-05-13 JP JP2013511568A patent/JP5743241B2/ja not_active Expired - Fee Related
- 2011-05-13 EA EA201291335A patent/EA022967B1/ru not_active IP Right Cessation
- 2011-05-13 ES ES11719487.8T patent/ES2595250T3/es active Active
- 2011-05-13 CN CN201180023073.7A patent/CN102883725B/zh active Active
- 2011-05-13 BR BR112012030006A patent/BR112012030006A2/pt not_active Application Discontinuation
- 2011-05-13 LT LTEP11719487.8T patent/LT2575822T/lt unknown
- 2011-05-13 MX MX2012013642A patent/MX2012013642A/es active IP Right Grant
- 2011-05-13 NZ NZ602730A patent/NZ602730A/en not_active IP Right Cessation
- 2011-05-13 SG SG2012073235A patent/SG184405A1/en unknown
- 2011-05-13 RS RS20160837A patent/RS55233B1/sr unknown
- 2011-05-13 MY MYPI2012004874A patent/MY160377A/en unknown
- 2011-05-13 SI SI201130986A patent/SI2575822T1/sl unknown
- 2011-05-13 ME MEP-2016-187A patent/ME02555B/me unknown
- 2011-05-13 WO PCT/EP2011/002369 patent/WO2011147536A2/en active Application Filing
- 2011-05-13 SG SG10201502252YA patent/SG10201502252YA/en unknown
- 2011-05-13 KR KR1020127029977A patent/KR101790371B1/ko active IP Right Grant
- 2011-05-13 AU AU2011257586A patent/AU2011257586B2/en not_active Ceased
- 2011-05-13 US US13/699,333 patent/US20140200203A1/en not_active Abandoned
- 2011-05-13 CA CA2794553A patent/CA2794553C/en not_active Expired - Fee Related
- 2011-05-13 DK DK11719487.8T patent/DK2575822T3/en active
- 2011-05-13 PL PL11719487T patent/PL2575822T3/pl unknown
- 2011-05-13 HU HUE11719487A patent/HUE029818T2/en unknown
- 2011-05-13 PT PT117194878T patent/PT2575822T/pt unknown
- 2011-05-13 EP EP11719487.8A patent/EP2575822B1/en active Active
- 2011-05-24 AR ARP110101784A patent/AR081765A1/es unknown
- 2011-05-24 UY UY0001033404A patent/UY33404A/es not_active Application Discontinuation
- 2011-05-24 TW TW100118106A patent/TWI473615B/zh not_active IP Right Cessation
-
2012
- 2012-09-27 IL IL222163A patent/IL222163B/en active IP Right Grant
- 2012-11-08 ZA ZA2012/08420A patent/ZA201208420B/en unknown
- 2012-11-23 CL CL2012003282A patent/CL2012003282A1/es unknown
- 2012-11-23 CO CO12212409A patent/CO6640244A2/es not_active Application Discontinuation
-
2013
- 2013-05-13 HK HK13105652.3A patent/HK1177893A1/zh not_active IP Right Cessation
-
2015
- 2015-10-15 US US14/883,898 patent/US9907807B2/en active Active
-
2016
- 2016-09-29 SM SM201600342T patent/SMT201600342B/it unknown
- 2016-10-06 HR HRP20161288TT patent/HRP20161288T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161288T1 (hr) | Topikalni farmaceutski pripravci koji sadrže mometazon furoat | |
| BR112014029758A2 (pt) | composição contendo n-metil-n-acilglucamina | |
| WO2013178701A3 (de) | Zusammensetzungen enthaltend fettalkohole, kationische tenside und n-acyl-n-methylglucamine | |
| BR112019004971A2 (pt) | gel para cuidados pessoais e método | |
| Behmanesh et al. | Effects of olive oil sitz bath on improvement of perineal injury after delivery | |
| NZ702472A (en) | Oil/water-emulsion-type topical compositions containing a retinoid | |
| RU2016116831A (ru) | Композиция | |
| BR112015032029A2 (pt) | uso de uma composição compreendendo óleo de peixe e suco para o tratamento de inflamação | |
| MY192590A (en) | Liquid skin-cleansing agent composition | |
| TR201903470T4 (tr) | Kişisel hijyen için formülasyon. | |
| BR112014007274A2 (pt) | preparação cosmética ou dermatológica para aplicação sobre a pele molhada ou úmida e método para cuidar da pele | |
| BR112015027436A8 (pt) | composição tópica e veículo para administração de ingredientes farmaceuticamente ou cosmeticamente ativos | |
| BR112014031306A2 (pt) | composição farmacêutica e respectivos usos | |
| HRP20200504T1 (hr) | Lokalni preparati farmaceutskih i medicinskih proizvoda koji sadrže kombinacije sukralfata, hijaluronske kiseline, arginina i prirodnog hidratantnog sredstva | |
| ES2562085B1 (es) | Crema para el tratamiento de pieles con estados descamativos y procedimiento de fabricación de dicha crema | |
| CN104721088A (zh) | 一种护手霜 | |
| PL428523A1 (pl) | Kompozycja zawierająca luteinę, zastosowanie kompozycji oraz sposób wytwarzania kompozycji | |
| PL402321A1 (pl) | Preparat do pielęgnacji skóry rąk | |
| TH153704A (th) | องค์ประกอบทางเภสัชกรรมสำหรับใช้เฉพาะที่ | |
| PE20141538A1 (es) | Composicion para ser aplicada a la piel, y uso de la misma | |
| Gallagher et al. | Comparison of emollient efficacy-a single centre, randomised, double-blind, bi-lateral comparison of two emollients prescribed in the UK for the management of dry skin conditions such as atopic eczema | |
| CN102908274A (zh) | 一种用于沐浴用品的清凉剂 | |
| PL227467B1 (pl) | Kompozycja kosmetyczna | |
| TH154104A (th) | ครีมดูแลผิวหนังอ่อนนุ่มที่แทรกซึมเร็ว | |
| HRP20240775T1 (hr) | Sastav koji sadrži kromoglicinsku kiselinu za liječenje dermatitisa |